Gene Therapy

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

A large-scale study indicates women are more likely to develop the inherited corneal condition

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision

The company shared 5-year results for lenadogene nolparvovec (Lumevoq), administered unilaterally and bilaterally to patients with Leber Hereditary Optic Neuropathy

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

Our top 10 print stories highlight the core content concepts we explored this year

Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

Collaboration and outside-the-box thinking present significant opportunities for science and industry

The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.

Gene therapy for nAMD represents significant advancements in the treatment of retinal conditions

Gene therapy was a major topic at the 2024 EURETINA and Retina Society meetings

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

Identifying all genetic culprits may improve diagnostics and prognoses

The US Food and Drug Administration issued designations for the allogeneic cell therapy candidate, a therapeutic for corneal oedema

XLRP often leads to blindness by middle age with no treatment options currently available

Investigators say the discovery highlights the importance of genetic consultation

Simply slowing disease progression is no longer enough